<DOC>
	<DOCNO>NCT01368926</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , 2-Part study evaluate pharmacokinetics safety RO4917523 healthy Japanese Caucasian volunteer . In Part 1 , healthy Japanese volunteer randomize receive 2 oral dos either RO4917523 placebo , washout period 21 day dose . In Part 2 , healthy Japanese Caucasian volunteer randomize cohort receive either RO4917523 placebo orally daily 14 day .</brief_summary>
	<brief_title>A Pharmacokinetic Study RO4917523 Healthy Japanese Caucasian Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy Japanese ( Part 1 + 2 ) Caucasian ( Part 2 ) adult , 18 50 year age Japanese subject must Japanese parent grandparent born Japan Caucasian subject must 4 Caucasian grandparent Body mass index ( BMI ) 18.5 26 kg/m2 , body weight least 45 kg Nonsmoker least 90 day prior dose Day 1 Participation clinical trial investigational drug within 90 day prior dose Day 1 . ( Volunteers participate Part 1 allow participate Part 2 vice versa ) History evidence clinically significant disease disorder Pregnant lactate woman Positive hepatitis B , hepatitis C HIV Positive drug screen test , positive cotinine test and/or positive alcohol test Any confirm significant allergic reaction drug , multiple allergy judgement investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>